Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial

mTOR inhibition reverses trastuzumab resistance via the hyperactivated PIK/AKT/mTOR pathway due to PTEN loss, by sensitising PTEN-deficient tumours to trastuzumab. The BOLERO-1 study assessed the efficacy and safety of adding everolimus to trastuzumab and paclitaxel as first-line treatment for patie...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	The lancet oncology Ročník 16; číslo 7; s. 816 - 829
Hlavní autoři:	Hurvitz, Sara A, Andre, Fabrice, Jiang, Zefei, Shao, Zhimin, Mano, Max S, Neciosup, Silvia P, Tseng, Ling-Min, Zhang, Qingyuan, Shen, Kunwei, Liu, Donggeng, Dreosti, Lydia M, Burris, Howard A, Toi, Masakazu, Buyse, Marc E, Cabaribere, David, Lindsay, Mary-Ann, Rao, Shantha, Pacaud, Lida Bubuteishvili, Taran, Tetiana, Slamon, Dennis
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	England Elsevier Ltd 01.07.2015 Elsevier Limited
Témata:	Adult Aged Aged, 80 and over Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biomarkers, Tumor - blood Breast cancer Breast Neoplasms - blood Breast Neoplasms - drug therapy Breast Neoplasms - mortality Breast Neoplasms - pathology Cancer therapies Chemotherapy Clinical trials Disease-Free Survival Dose-Response Relationship, Drug Double-Blind Method Drug Administration Schedule Endocrine therapy Everolimus Female Hematology, Oncology and Palliative Medicine Humans Kaplan-Meier Estimate Maximum Tolerated Dose Medical prognosis Metastasis Middle Aged Neoplasm Invasiveness - pathology Neoplasm Staging Ovarian cancer Paclitaxel - administration & dosage Paclitaxel - adverse effects Patients Proportional Hazards Models Receptor, ErbB-2 - blood Sirolimus - administration & dosage Sirolimus - adverse effects Sirolimus - analogs & derivatives Survival Analysis Trastuzumab Treatment Outcome Tumors Young Adult
ISSN:	1470-2045, 1474-5488, 1474-5488
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!